Potential new drug for tuberculosis

August 5, 2013
Some strains of Mycobacterium tuberculosis, the bacterium that causes TB, have become resistant to most antibiotics — but researchers hope that a new synthetic molecule will be a more formidable weapon to fight them. Credit: CDC/ Dr. Ray Butler

A new drug capable of inhibiting growth of Mycobacterium tuberculosis is reported this week in Nature Medicine. The findings may improve therapeutic options for the treatment of drug resistant tuberculosis (TB).

One-third of the world's population is latently infected with M. tuberculosis and more than a million people die of TB each year. Multidrug- of M. tuberculosis are spreading, and therefore the need to develop new and improved drugs is urgent.

Kevin Pethe and colleagues screened a chemical library for inhibitors of M. tuberculosis growth in and identified imidazopyrimidine amides as potential candidates. The team then optimized these chemicals in order to generate the compound Q203. This compound, which showed efficacy in vitro and in a mouse model of established TB, targets part of the M. tuberculosis electron chain and therefore inhibits ATP synthesis—which is needed for cellular energy production.

The findings support the concept of targeting ATP synthesis to potentially eradicate both active and latent M. tuberculosis and provide a new candidate for clinical validation.

Explore further: Improving detection of drug-resistant tuberculosis

More information: Nature Medicine (2013) doi:10.1038/nm.3262

Related Stories

FDA approves first new tuberculosis in 40 years

December 31, 2012

The Food and Drug Administration says it has approved a Johnson & Johnson tuberculosis drug that is the first new medicine to fight the deadly infection in more than four decades.

Recommended for you

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Mosquitoes, Zika and biotech regulation

September 19, 2016

In a new Policy Forum article in Science, NC State professor Jennifer Kuzma argues that federal authorities are missing an opportunity to revise outdated regulatory processes not fit for modern innovations in biotechnology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.